Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function.
Conor De BarraMohammed KhalilArimin MatCliona O'DonnellFerrah ShaamileKiva BrennanDonal O'SheaAndrew E HoganPublished in: Obesity (Silver Spring, Md.) (2023)
The restoration, by GLP-1 therapy, of NK cell functionality in PWO may be contributing to the overall benefits being seen with this class of medication.